nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
CD8+ T cells expressing IL-10 are associated with a favourable prognosis in lung cancer
|
Miotto, D. |
|
2010 |
69 |
3 |
p. 355-360 6 p. |
artikel |
2 |
Contents
|
|
|
2010 |
69 |
3 |
p. v-vi nvt p. |
artikel |
3 |
Corrigendum to “Emerging profile of cetuximab in non-small cell lung cancer” [Lung Cancer 68 (2010) 332–337]
|
Ettinger, David S. |
|
2010 |
69 |
3 |
p. 367- 1 p. |
artikel |
4 |
Editorial Board
|
|
|
2010 |
69 |
3 |
p. iii- 1 p. |
artikel |
5 |
Estimation of an optimal chemotherapy utilisation rate for lung cancer: An evidence-based benchmark for cancer care
|
Jacob, Susannah |
|
2010 |
69 |
3 |
p. 307-314 8 p. |
artikel |
6 |
Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients
|
Chen, Xi |
|
2010 |
69 |
3 |
p. 348-354 7 p. |
artikel |
7 |
KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies
|
Mao, Chen |
|
2010 |
69 |
3 |
p. 272-278 7 p. |
artikel |
8 |
Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer
|
Laack, Eckart |
|
2010 |
69 |
3 |
p. 259-264 6 p. |
artikel |
9 |
Pemetrexed and cisplatin with concurrent radiotherapy for locally advanced non-small cell and limited disease small cell lung cancer: Results from 2 phase I studies
|
Surmont, V. |
|
2010 |
69 |
3 |
p. 302-306 5 p. |
artikel |
10 |
Prognostic significance of matrix metalloproteinase-1 levels in peripheral plasma and tumour tissues of lung cancer patients
|
Li, Min |
|
2010 |
69 |
3 |
p. 341-347 7 p. |
artikel |
11 |
PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers
|
Jin, Guang |
|
2010 |
69 |
3 |
p. 279-283 5 p. |
artikel |
12 |
Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients
|
Pircher, Andreas |
|
2010 |
69 |
3 |
p. 265-271 7 p. |
artikel |
13 |
Re-challenge chemotherapy for relapsed non-small-cell lung cancer
|
Nagano, Tatsuya |
|
2010 |
69 |
3 |
p. 315-318 4 p. |
artikel |
14 |
Recurrent EML4–ALK-associated lung adenocarcinoma with a slow clinical course
|
Murakami, Shuji |
|
2010 |
69 |
3 |
p. 361-364 4 p. |
artikel |
15 |
Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: A multi-center phase II study
|
Ichikawa, Motoshi |
|
2010 |
69 |
3 |
p. 319-322 4 p. |
artikel |
16 |
Snail nuclear expression parallels higher malignancy potential in neuroendocrine lung tumors
|
Galván, J.A. |
|
2010 |
69 |
3 |
p. 289-295 7 p. |
artikel |
17 |
Stereotactic body radiotherapy using real-time tumor tracking in octogenarians with non-small cell lung cancer
|
van der Voort van Zyp, Noëlle C. |
|
2010 |
69 |
3 |
p. 296-301 6 p. |
artikel |
18 |
Surgical treatment of oligometastatic non-small cell lung cancer
|
Pfannschmidt, Joachim |
|
2010 |
69 |
3 |
p. 251-258 8 p. |
artikel |
19 |
The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer
|
Chang, Myung Hee |
|
2010 |
69 |
3 |
p. 323-329 7 p. |
artikel |
20 |
The value of day 8 blood count in treatment decisions when using oral vinorelbine in non-small cell lung cancer
|
Myerson, J.S. |
|
2010 |
69 |
3 |
p. 365-366 2 p. |
artikel |
21 |
Unsuspected pulmonary emboli in lung cancer patients: The impact on survival and the significance of anticoagulation therapy
|
Sun, Jong-Mu |
|
2010 |
69 |
3 |
p. 330-336 7 p. |
artikel |
22 |
Usefulness of melanoma antigen (MAGE) gene analysis in tissue samples from percutaneous needle aspiration biopsy of suspected lung cancer lesions
|
Kim, Hana |
|
2010 |
69 |
3 |
p. 284-288 5 p. |
artikel |
23 |
VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab
|
Carbone, David P. |
|
2010 |
69 |
3 |
p. 337-340 4 p. |
artikel |